Treatment Rates and Compliance to Treatment in Patients With Familial Hypercholesterolemia

NCT04494464 | Completed

• 1 other identifier: Hypercholesterolemia
• Study Type: observational
• Target: 367
• Locations: 0 countries
• Sites: N/A

Brief Summary

Familial hypercholesterolemia is a genetic disease characterized by increased levels of low density lipoprotein cholesterol (LDL-C). It is underdiagnosed and undertreated despite relatively high prevalence and significant association with increased mortality.

Conditions

Familial Hypercholesterolemia

Outcome Measures

Primary Outcomes (1)

• Treatment rates

  Patients with a serum LDL-C≥250 mg/dL were identified from the database of our hospital. Dutch Lipid Clinical Network Criteria was used to classify patients as definite, probable and possible FH. Patients were reached by phone and a questionnaire was applied. The questionnaire consisted of questions related with clinical and physical examination findings defined in theDutch Lipid Clinical Network Criteria. Total cholesterol, LDL-C, HDL-C, triglyceride levels were obtained from the medical records. Patients were asked whether they were using lipid lowering drugs. If they were not using, the cause of this was asked. By this way, we determined the rate of use of lipid lowering drugs in patients with LDL-C≥250 mg/dL and have definite, probable or possible familial hypercholesterolemia

  January 2010 and December 2016

Study Arms (1)

Patients with LDL cholesterol ≥250 mg/dL

Patients older than 18 years old and have a serum LDL-C≥250 mg/dL between January 2010 and December 2016. Patients with a serum TSH≥10 mIU/mL, patients with glomerulonephritis or nephrotic syndrome, patients with ALT or AST higher than 3 times of normal limits and patients with serum triglyceride \>400 mg/dL were excluded.

Other: No intervention

Interventions

No intervention OTHER

Patients with LDL cholesterol ≥250 mg/dL

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients older than 18 years old and have a serum LDL-C≥250 mg/dL

You may qualify if:

• Patients older than 18 years old and have a serum LDL-C≥250 mg/dL

You may not qualify if:

• Patients who refuse dto interview
• Serum TSH≥10 mIU/mL
• Glomerulonephritis or nephrotic syndrome
• ALT or AST higher than 3 times of normal limits
• Serum triglyceride \>400 mg/dL

Sponsors & Collaborators

• Ankara Yildirim Beyazıt University: lead

Related Publications (1)

• Yaman S, Ozdemir D, Akman BT, Cakir B, Ersoy O. Awareness, treatment rates, and compliance to treatment in patients with serum LDL cholesterol higher than 250 mg/dL, and possible, probable, or definite familial hypercholesterolemia. Postgrad Med. 2021 Mar;133(2):146-153. doi: 10.1080/00325481.2020.1805212. Epub 2020 Sep 23.

  PMID: 32744105 DERIVED

MeSH Terms

Conditions

Hyperlipoproteinemia Type II

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hyperlipoproteinemias; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: July 24, 2020
• First Posted: July 31, 2020
• Study Start: January 1, 2017
• Primary Completion: May 1, 2017
• Study Completion: May 1, 2017
• Last Updated: July 31, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share